BD211
Phase 1- Indications
- Beta-0/beta-0 transfusion-dependent beta-thalassemia
Company intelligence / Profile preview
WellYearn Technology (Shenzhen) Company Limited
Shenzhen, Chinachictr.org.cn ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
A product registration clinical trial for a therapy or device named WY‑2201 focused on red blood cell life extension has been registered by WellYearn Technology. Detailed results are not yet published.
- Therapeutic areas
- Hematology
- Modalities
- DiagnosticsDevice-based therapeutics
- Industry
- Therapeutic Medical Devices
02
Drug pipeline
1 assetBeyond the preview
Go deeper on WellYearn Technology (Shenzhen) Company Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WellYearn Technology (Shenzhen) Company Limited.